Article published on 2026-2-24

Sunvozertinib A Next-Generation EGFR Exon 20 Insertion Inhibitor Transforming NSCLC Therapy

Manoj Kumbhare, Dhiraj Gadekar*, Siddhi Chandak, Samiksha Mankar

SMBT College of Pharmacy, Nandi-hills, Dhamangaon, Igatpuri, Nashik – 422403, India

***Correspondence Author:**
Dhiraj Gadekar
SMBT College of Pharmacy, Nandi-hills, Dhamangaon, Igatpuri, Nashik – 422403, India
E-mail: gadekardhiraj544@gmail.com

Applied Physiology, 2026: e20260005

Abstract Sunvozertinib (DZD9008) is an emerging next-generation, highly selective EGFR tyrosine kinase inhibitor (TKI) designed to target EGFR exon 20 insertion (Ex20ins) mutations, a subtype of non–small cell lung cancer (NSCLC) associated with poor response to earlier-generation EGFR TKIs. Patients with these mutations typically exhibit intrinsic resistance to approved standard EGFR inhibitors due to the altered conformation of the kinase domain. Consequently, therapeutic options have remained limited, and platinum-doublet chemotherapy has historically been the primary systemic treatment. Recently developed agents such as amivantamab and mobocertinib have improved response rates, yet challenges related to tolerability, CNS penetration, and durability of benefit persist. Sunvozertinib aims to address these limitations through rational structural design, optimized kinase selectivity, and improved safety–efficacy balance.

Preclinical studies have shown potent inhibition of a broad spectrum of EGFR Ex20ins variants while sparing wild-type EGFR, suggesting a reduced risk of dose-limiting toxicities commonly seen with non-selective EGFR blockade. Sunvozertinib has also demonstrated promising CNS activity in animal models-an important feature for NSCLC patients, who frequently develop brain metastases. Early-phase clinical trials, including the WU-KONG series, have reported promising clinical efficacy, including objective response rates ranging from 44-60% in previously treated patients and meaningful activity in treatment-naïve cohorts. The tolerability profile of the drug seems manageable, with diarrhea, rash, and stomatitis among the most commonly observed adverse events; these, however, tend to be milder compared with other agents targeting EGFR Ex20ins.

Keywords TKI, Ex20ins, NSCLC, Sunvozertinib, WU-KONG

1. Introduction

EGFR exon 20 insertion mutations define a distinct clinically important subset of non–small cell lung cancer. Whereas canonical activating EGFR mutations including exon 19 deletions and L858R comprise the majority of EGFR-mutant disease, ex20ins represent a small but meaningful fraction-estimated in pooled series to comprise roughly 0.7% of all NSCLC and about 6% of EGFR-positive NSCLC-affecting thousands of patients worldwide each year[1]. Patients harboring ex20ins tend to present with the same clinicopathologic features as other EGFR-mutant cases (adenocarcinoma histology, never/light smoking, enrichment in Asian populations) but show a poorer

DOI: 10.62958/j.cjap.2026.005
cjap.ytbmed.net

Published by Asian BioMed Innovation Press

prognosis because conventional EGFR tyrosine kinase inhibitors produce little clinical benefit[1,2].

The biochemical basis for this clinical resistance lies in structural consequences of insertions within exon 20. Most ex20ins are situated at or just after the C-helix and cause either an inward shift or steric crowding of the ATP-binding pocket, reducing access for earlier-generation EGFR TKIs that were designed to fit the conformation produced by exon 19 deletions or L858R. Succinctly, the mutated kinase remains active but is less permissive to the binding geometry of standard inhibitors; this is a hypothesis supported by structural, biochemical, and cell-line data. This has driven efforts to design mutant-selective agents able to accommodate the altered pocket. A minor proportion of rare ex20ins (e.g., A763_Y764insFQEA) sit at different positions, retaining sensitivity to some classical TKIs, which underlines the molecular heterogeneity of this group[3].

Until recently, platinum-based chemotherapy was the mainstay for patients with ex20ins. Over the last decade a targeted-therapy landscape has emerged: amivantamab (a bispecific anti-EGFR/MET antibody) received regulatory approval based on single-arm activity in platinum-pretreated patients, and small-molecule agents such as mobocertinib and poziotinib have shown variable efficacy but substantial on-target toxicities that limit dosing. Market and regulatory fortunes have varied-mobocertinib's clinical benefit versus chemotherapy has been questioned, and poziotinib's development has been constrained by tolerability-so clinicians still face difficult trade-offs between efficacy and safety when selecting therapy for ex20ins patients. Several newer TKIs and combination strategies are under investigation, reflecting active but unsettled therapeutic terrain[4].

Against this backdrop, sunvozertinib (Zegfrovy) has recently emerged as a focus of interest. In mid-2025 the U.S. Food and Drug Administration granted accelerated approval for sunvozertinib for adults with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations following progression on platinum-based chemotherapy. The approval was supported by clinical trial data demonstrating meaningful objective response rates and duration of response in the pretreated population, and by a comprehensive regulatory dossier and label that detail dosing and safety considerations. This regulatory milestone-together with accumulating trial evidence and the practical need to define sunvozertinib's comparative role among other ex20ins therapies-provides a timely rationale for a focused, critical review of the drug's chemistry, preclinical rationale, clinical efficacy, toxicity profile, biomarker strategies, and place in therapy[3,5].

2. Chemistry of Sunvozertinib

Sunvozertinib, which goes by the brand name Zegfrovy and has been referred to by its research name DZD9008, is a small-molecule, irreversible tyrosine kinase inhibitor engineered to target various mutant forms of the epidermal growth factor receptor, especially EGFR exon 20 insertion variants. The chemical name of this compound is $C_{39}H_{35}ClFN_7O_3$, having a molecular weight of approximately 584.09



Figure 1: Structure of Sunvozertinib

g/mol[6].

Its IUPAC name reflects a complex structure featuring a pyrimidine core, a substituted aniline, a dimethylamino-pyrrolidine side chain, and an acrylamide moiety: N-{5-[(4-{[5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl]amino}pyrimidin-2-yl)amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl}prop-2-enamide[7].

Structurally, sunvozertinib was engineered to achieve high potency against mutant EGFR while sparing wild-type EGFR as much as possible. Preclinical data show that in cell-based assays, sunvozertinib inhibits phosphorylation of EGFR harboring exon 20 insertions at concentrations 2- to 10-fold lower than those required to inhibit wild-type EGFR[1,4].

This selectivity reduces off-target toxicity, an important design feature since early EGFR TKIs have caused dose-limiting side effects through the inhibition of wild-type EGFR.

From a medicinal chemistry perspective, the molecule contains several key design features:

• A pyrimidine scaffold that drives binding into the ATP pocket of EGFR, with an open C-5 position that allows for structural variation within the mutant receptor.

• A halogen-substituted aniline comprising chlorine and fluorine on the phenyl ring to optimize binding affinity and contribute to kinetic stability.

• An acrylamide "warhead" that allows for irreversible covalent bonding with a cysteine residue in the EGFR kinase domain, which enhances binding durability and selectivity.

• Dimethylamino-pyrrolidine side chain projects into the solvent channel, enhancing the solubility, pharmacokinetics, and metabolic stability while avoiding steric clashes. Preclinical chemistry studies show that this moiety contributes to a favorable PK profile, such as longer half-life and better oral exposure[8].

3. Pharmacology

a) Kinase Selectivity and Potency

Sunvozertinib was specifically engineered by structure-guided design to exhibit high potency against EGFR ex20ins mutations with minimal activity against wild-type EGFR. It exhibits nanomolar activity across a diverse range of ex20ins variants, and its selectivity for mutant over wild-type EGFR is 2-10 times higher than earlier TKIs, overcoming the therapeutic limitations imposed by excessive wild-type inhibition. Sunvozertinib forms an irreversible covalent bond with Cys797, its scaffold being optimized to fit the sterically altered ATP pocket generated by ex20ins mutations, maintaining stable binding across multiple conformations. Kinase profiling confirms a clean selectivity profile, with limited off-target activity against other HER receptors or against unrelated kinases. These properties collectively enable potent, mutation-agnostic EGFR inhibition while supporting a more manageable safety profile and higher clinically effective exposures[4].

b) Pharmacokinetics and Distribution

Sunvozertinib demonstrates a pharmacokinetic profile well-suited for once-daily oral dosing, with good absorption and a median Tmax of 4–6 hours. Drug exposure increases in a dose-proportional manner over the therapeutic range, and steady state is attained within 10–15 days with approximately threefold accumulation. The agent is ~90% protein-bound and demonstrates a very large volume of distribution (>2,000 L), indicating extensive tissue penetration. Its ~50-hour half-life supports durable systemic levels and continuous pathway inhibition[6].

Sunvozertinib is primarily metabolized by CYP3A into the active metabolite, DZ0753, and is eliminated mostly in feces (~80%) with a minimum amount of renal excretion. Food has little impact on bioavailability, allowing flexible dosing. Importantly, the drug shows lower interpatient PK variability than earlier ex20ins inhibitors, which increases dosing reliability.

Clinically, dosing was optimized differently for various regions: the studies in China assessed 200–300 mg daily, while the U.S. approval set 200 mg once daily as the recommended dose to balance efficacy with tolerability[9].

c) Molecular Design and Safety Considerations

The molecular blueprint of sunvozertinib integrates multiple structural elements for the optimization of both efficacy and tolerability:

i. Mutant-Selective Binding Strategy

The pyrimidine core and the halogenated aniline group have been designed to exploit conformational features of ex20ins variants. The acrylamide "warhead" provides precision covalent attachment to Cys797, enhancing mutant selectivity and minimizing wild-type EGFR occupancy at equivalent plasma levels, reducing rates of rash, diarrhea, and mucosal toxicities typical of high-WT-EGFR inhibition[10].

ii. Solubility and Metabolic Optimization

The dimethylamino-pyrrolidine moiety enhances aqueous solubility while reducing metabolic clearance. This modification opens the solvent channel, thus mitigating steric clashes created by ex20ins structural distortions[5,9].

iii. Safety-driven structural constraints

Preclinical medicinal chemistry efforts purposefully minimized molecular features associated with HER2 cross-reactivity and pan-ERBB inhibition, which are common among earlier multi-kinase ex20ins inhibitors with significant dermatologic and gastrointestinal toxicities. Sunvozertinib achieves a more favorable therapeutic index by restricting interaction with off-target kinases[11].

iv. Covalent Inhibition Considerations

While irreversible TKIs theoretically incur additional risks from sustained inhibition in normal tissues, the design of sunvozertinib mitigates this risk through the engineering of selectivity and control over systemic exposure. Class-related safety signals, however, such as ILD, remain an important clinical consideration[12].

4. Mechanism of Action

Sunvozertinib, formerly known as DZD9008, is an irreversible covalent inhibitor of EGFR that was specifically optimized for EGFR ex20ins mutations, a class of alterations that structurally disrupt the kinase pocket and confer resistance to classical EGFR TKIs. The drug selectively targets mutant EGFR by binding to the catalytic cleft and forming a covalent bond with cysteine 797 in the ATP-binding site. This irreversible mode of action enables prolonged suppression of EGFR signaling during fluctuations in plasma concentrations over the dosing interval[2].

The structural design of sunvozertinib allows it to fit within the sterically crowded active site created by exon 20 insertions, these being regions involving distortions in the C-helix and loop rearrangements that prevent the binding of bulky first- and second-generation TKIs. Accommodating these conformation shifts maintains nanomolar inhibitory activity for sunvozertinib against a wide spectrum of ex20ins variants, while it shows markedly reduced affinity for wild-type EGFR, helping to minimize classic EGFR-related toxicities such as rash and diarrhea[12].

Downstream, sunvozertinib effectively blocks phosphorylation of EGFR and associated pathways, including RAS–RAF–MEK–ERK and PI3K–AKT, inhibiting tumor-cell proliferation and survival. An active oxidative metabolite, DZ0753, further contributes to pathway inhibition with similar mutation-selective properties. Preclinical studies confirm that this drug's mutation-selective, covalent mechanism translates into potent tumor regression in xenograft and patient-derived models[13].

5. Preclinical Studies

Preclinical studies of sunvozertinib established its potent and mutation-selective inhibition of EGFR exon 20 insertion-driven signaling. Across cellular systems and animal models, the drug consistently produced strong pathway suppression and robust antitumor activity, forming the foundation for its clinical development.

6. Clinical trial data

The clinical development of sunvozertinib has



Figure 2: MOA of Sunvozertinib

Table 1: Preclinical Data of Sunvozertinib

Category	Key Findings
In vitro potency	• Nanomolar inhibition of EGFR phosphorylation across major ex20ins variants (A767_V769dup, S768_D770dup, D770_N771ins) • Strong suppression of ERK and AKT signaling • Dose-dependent inhibition of cell proliferation and induction of apoptosis (e.g., cleaved PARP) [14]
Cell-line models used	• Ba/F3 engineered cells expressing ex20ins variants • Human NSCLC cell lines with endogenous or engineered EGFR ex20ins mutations[15]
Xenograft efficacy	• Rapid and deep tumor regressions in mouse models with ex20ins-expressing cell lines • Exposure-dependent antitumor responses • Durable pathway suppression confirmed by reduced pEGFR, pERK, pAKT, and decreased Ki67 [16]
Patient-derived xenografts (PDX)	• Strong tumor shrinkage in PDX models harboring native ex20ins mutations • Validates efficacy in tumors with real-world genomic architecture[17]
Pharmacodynamic biomarkers	• pEGFR suppression strongly correlates with tumor regression • Inhibition of downstream ERK and AKT pathways mirrors antitumor activity[18]
Active metabolite (DZ0753)	• Formed via CYP3A metabolism • Shows potency similar to parent compound against ex20ins • Contributes to sustained pathway inhibition and overall efficacy[19]
Selectivity profile	• High selectivity for ex20ins and select other EGFR mutants • Weak inhibition of wild-type EGFR and HER2 at clinical concentrations • Minimal off-target kinase interactions at therapeutic doses[20]
Heterogeneity of sensitivity	• Most ex20ins variants highly sensitive • A few rare insertion subtypes show reduced sensitivity due to structurally distinct insertion geometry[21]
Identified resistance mechanisms	• On-target secondary EGFR mutations (including near Cys797) • Activation of bypass pathways: MET amplification, HER2 upregulation, occasional IGF1R activation • EMT-like phenotypic changes in long-term culture models[22]
Implications for therapy	• Supports use in a wide range of ex20ins patients • Highlights need for molecular genotyping and resistance monitoring • Provides rationale for combination therapy (e.g., MET or HER2-targeted agents) [14,23]

progressed rapidly on the strength of compelling antitumor activity in EGFR exon 20 insertion–positive NSCLC. Across phase I–III studies, the drug has demonstrated meaningful and durable responses in both pretreated and treatment-naïve patients. Its favorable safety profile and consistent efficacy across insertion subtypes supported accelerated FDA approval, with confirmatory trials now underway.

7. Safety profile and management

Sunvozertinib's toxicity profile reflects its mutation-selective EGFR inhibition: overall tolerability is improved versus earlier, less-selective exon-20 agents, but class-typical adverse events (diarrhea, dermatologic events) and several important laboratory and organ-system toxicities remain clinically relevant. Safety varied by dose in clinical development (200 mg vs 300 mg daily), with higher rates of gastrointestinal and laboratory toxicities observed at 300 mg; the U.S. prescribing information therefore recommends 200 mg once daily as the starting dose[29].

8. Conclusion

Sunvozertinib represents a significant step forward in the therapeutic paradigm for EGFR exon 20 insertion-positive NSCLC, a subpopulation that has been historically underserved due to the intrinsic resistance of these mutations to earlier generations of

Table 2: Clinical study details of sunvozertinib

Study/Phase	Population	Dose	Key Efficacy Outcomes	Safety / Notes
Phase I (dose-escalation & expansion)	Advanced/metastatic NSCLC with EGFR exon 20 insertions (heavily pretreated; some with brain metastases)	100–300mg QD	ORR (all evaluable): 37.5% (n=56) At 200–300 mg: ORR ~41% Responses seen across numerous ex20ins subtypes	Mostly grade 1–2 AEs Early signal of favorable WT-EGFR sparing toxicity profile[24]
WU-KONG1B (Phase II; pivotal)	Platinum-pretreated NSCLC with EGFR ex20ins mutations (n=85 in primary cohort)	200 mg QD (registrational dose)	Confirmed ORR: 46% (95% CI: 35–57) Median DoR: 11.1 months DCR: ~89–90% Activity seen in patients with brain mets	Common TRAEs: diarrhea, CPK elevation, rash, anemia, lipase ↑ Grade ≥3 AEs manageable; ~36% dose reductions; ~6% discontinuation[25]
WU-KONG1B (pooled 200 + 300 mg)	Combined analysis across dose cohorts	200–300 mg QD	ORR up to ~53% in pooled subgroup analyses Consistent responses across insertion subtypes	No fatal treatment-related AEs reported[26]
WU-KONG15 (Phase II; first-line)	Treatment-naïve metastatic NSCLC with EGFR ex20ins (n=26)	200 mg QD	ORR: 73.1% Median PFS: 10.1 months Median DoR: 10.5 months OS (immature): 23.1 months	Toxicity similar to prior studies Demonstrates strong frontline potential[16]
WU-KONG28 (Phase III; confirmatory)	Treatment-naive EGFR ex20ins NSCLC; randomized vs platinum chemotherapy	200 mg QD	Results pending (trial fully enrolled) Will confirm survival benefit to convert FDA accelerated approval to full approval	Designed to evaluate long-term safety and first-line superiority / non-inferiority[26,27]
Regulatory Milestone (2025)	–	200 mg QD approved dose	FDA Accelerated Approval (July 2, 2025) for metastatic NSCLC with EGFR ex20ins after platinum chemotherapy	Approval based on WU-KONG1B efficacy and safety results[28]

EGFR inhibitors. Through rational, structure-guided design, sunvozertinib achieves high mutant selectivity, potent irreversible inhibition of EGFR, and broad activity against various diverse ex20ins subtypes with an improved therapeutic index over prior agents. Preclinical evidence demonstrates robust pathway suppression, durable tumor regression, and a clear mechanistic rationale for clinical benefit.

Sunvozertinib has produced meaningful and durable responses in both previously treated and treatment-naïve populations across phase I and II trials, including the pivotal WU-KONG1B study, with efficacy across molecular subtypes and patient subgroups. The safety profile, with primarily manageable gastrointestinal, dermatologic, and laboratory abnormalities, further supports clinical applicability but illustrates the need for active monitoring for class-associated risks of ILD and CPK elevation. The FDA's accelerated approval of the 200 mg once-daily dose underlines its therapeutic promise and the substantial unmet need it addresses.

As confirmatory phase III trials mature, sunvozertinib will likely reshape the standard of care for EGFR ex20ins-mutated NSCLC. Ongoing studies to elucidate resistance mechanisms, rational

combinations, CNS activity, and long-term outcomes will continue to define its optimal utilization. Overall, available data establish sunvozertinib as a next-generation, mutation-selective TKI with the potential to dramatically alter the natural history of this difficult molecular subgroup.

Conflict of Interest

The authors declare that they have no conflicts of interest.

References

1. Mitsudomi T. Sunvozertinib : shining light on lung cancer ' s exon 20 fight. 2025;14(12):334–40.
2. Sangwan K, Agarwal G. Sunvozertinib: a Promising Oral EGFR Inhibitor Approved for NSCLC with EGFR Ex20ins Mutations. Invest New Drugs. 2025 Oct;43(5):1177–89.
3. Hayashi H. Sunvozertinib: the next candidate of TKI for NSCLC. Lancet Respir Med. 2024 Mar;12(3):185–6.
4. Wang M, Yang JC hsin, Mitchell PL, Fang J, Camidge DR, Nian W. Sunvozertinib , a Selective EGFR Inhibitor for Previously Treated Non – Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. 2022;(July).
5. Dhillon S. Sunvozertinib: First Approval. Drugs [Internet]. 2023;83(17):1629–34. Available from: https://doi.org/10.1007/s40265-023-01959-5
6. Niu X, Zhao W, Yu B. Sunvozertinib (Zegfrovy): an oral EGFR inhibitor that irreversibly targets exon20ins in NSCLC. Trends Pharmacol Sci. 2025 Dec;46(12):1269–70.
7. Lawrence L. EGFR exon 20-targeting sunvozertinib granted accelerated approval for advanced NSCLC. Vol. 131, Cancer. United States; 2025. p. e70091.
8. [China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage □ non-small cell lung cancer (version 2023)]. Zhonghua Yi Xue Za Zhi. 2023 Oct;103(40):3160–73.
9. Wang M, Fan Y, Sun M, Wang Y, Zhao Y, Jin B, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir Med [Internet]. 2024 Mar 1;12(3):217–24. Available from: https://doi.org/10.1016/S2213-2600(23)00379-X
10. Seo D, Lim JH. Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer. Int J Mol Sci. 2024 May;25(11).
11. Xu Y, Chen M, Gao X, Liu X, Zhao J, Zhong W, et al. Efficacy and safety of sunvozertinib monotherapy as first-line treatment in NSCLC patients with EGFR exon 20 insertion mutations: A phase 2, single-center trial. Cancer Lett. 2025 Oct;630:217904.
12. Liu H, Qin J, Qian X. Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming. Cancer Control. 2024;31:10732748241292782.
13. Cao LQ, Xie Y, Chen X, Patel H, Yuan L, Wurpel J, et al. Genetic modulation of ABCB1: Sunvozertinib reverses ABCB1-mediated multidrug resistance in cancer cells. Cancer Genet. 2025 Dec;300–301:47–57.
14. Zhang H, To KKW. Serum creatine kinase elevation following tyrosine kinase inhibitor treatment in cancer patients: Symptoms, mechanism, and clinical management. Clin Transl Sci. 2024 Nov;17(11):e70053.
15. Gawli CS, Patil CR, Patel HM. A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Bioorg Med Chem. 2025 Jun;123:118146.
16. Miyamura BV, Mambetsariev I, Fricke J, Arias-Romero J, Cadman K, Shrestha S, et al. Current paradigm of EGFR(ins20) in non-small cell lung cancer: A long way forward. Med (New York, NY). 2025 Sep;6(9):100803.
17. Wang M, Xu Y, Huang WT, Su WC, Gao B, Lee CK, et al. Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations. Lung Cancer. 2025 Jan;199:108053.
18. Xu Y, Yang JCH, Zhao Y, Doucet L, Zhou J, Wang Y, et al. Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation. Cell reports Med. 2025 May;6(5):102121.
19. Hamada A, Suda K, Nishino M, Obata K, Oiki H, Fukami T, et al. Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2024 Jan;19(1):71–9.
20. Yan W, Yang N, Wang G, Bao W, Liang Q, Lv T, et al. Brain Metastatic Tumor Flare After Sunvozertinib Dose Reduction in a Patient with Surgical Resected EGFR ex20ins NSCLC. Onco Targets Ther. 2025;18:1347–52.
21. Haider E, Akhtar I, Taj J, Ekouo J. Sunvozertinib in EGFR exon 20 insertion-mutated non-small cell lung cancer: expanding targeted therapy beyond standard EGFR inhibitors: a correspondence. Ann Med Surg. 2025 Dec;87(12):9057–8.
22. Suay G, Martín-Martorell P, Aparisi F, Arnal M, Guirado M, Azkárate A, et al. A real-world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations. Clin Transl Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex. 2025 Jun;27(6):2568–78.
23. Luan T, Lin X, Xie X, Yang G, Wang S, Hao J, et al. First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma. Anticancer Drugs. 2024 Sep;35(8):757–60.
24. Zhou J, Han H. Sunvozertinib Monotherapy in Advanced Lung Adenocarcinoma with EGFR Exon 20 Insertion and High PD-L1 Expression: A Case Report. Cancer Manag Res. 2025;17:2069–76.
25. Yang JCH, Wang M, Doucet L, Fan Y, Lv D, Sun M, et al. Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). J Clin Oncol Off J Am Soc

Clin Oncol. 2025 Oct;43(29):3198–208.
26. Li M, Soo RA. Will "Sun"-WUKONG, the monkey king, conquer EGFR exon 20 insertion mutation positive non-small cell lung cancer? Vol. 14, Translational lung cancer research. China; 2025. p. 323–7.
27. Wang Y, Zheng J, Wang J, Sheng L, Qu J, Zhou J. Case Report: A Rare EGFR 20 Insertion Variant, P772_H773insGNP Mediates Resistance to Sunvozertinib but Is Sensitive to Furmonertinib. Cancer Manag Res. 2025;17:2277–85.
28. Zhu H, Tang H, Peng H, Ding W. Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR Exon 20 S768I Mutant Lung Adenocarcinoma: A Case Report and Review of the Literature. Case Rep Oncol. 2025;18(1):220–30.
29. Kobayashi IS, Shaffer W, Viray H, Rangachari D, VanderLaan PA, Kobayashi SS, et al. The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors. JTO Clin Res reports. 2024 Jan;5(1):100614.
30. Xie K, Wang J, Jiang J, Deng Z, Hu Q, Wang D. Efficacy and safety outcomes of emerging EGFR-TKIs for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations: A systematic review and meta-analysis. Oncol Lett. 2025 Jun;29(6):316.
31. Park J, Lee B, Song JY, Sung M, Kwon MJ, Kim CR, et al. Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine. Pathology. 2024 Aug;56(5):653–61.
32. Zwierenga F, Zhang L, Melcr J, Schuuring E, van Veggel BAMH, de Langen AJ, et al. The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling. Lung Cancer. 2024 Nov;197:107973.
33. Ding K, Peng Z, Liu D, Xu Y. Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation. Vol. 22, Journal of translational medicine. England; 2024. p. 761.
34. Shi Y, Xu Y, Wang M. Current clinical practice and physicians' insights on Chinese patients with advanced non-small cell lung cancer habouring epidermal growth factor receptor 20 insertion mutation. BMC Cancer. 2024 Aug;24(1):1043.
35. Sentana-Lledo D, Academia E, Viray H, Rangachari D, Kobayashi SS, VanderLaan PA, et al. EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates. Transl lung cancer Res. 2023 Jul;12(7):1590–610.